Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Catalio Capital Management
BioCentury | Feb 20, 2025
Management Tracks
Hilberdink becomes president, U.S. human pharma at Boehringer
Plus: Nisa Leung leaves Qiming, and updates from Northsea, Ventus, Arima and Gate
BioCentury | Dec 20, 2024
Management Tracks
New business, medical and technology heads at Neutrolis
Plus: Noema hires Volker Knappertz as EVP of R&D, and updates from Lux, COA, Imbed and March Bio
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Aug 30, 2024
Finance
Finance Report: RA, Forbion back immunology play Navigator to develop bispecific
Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
BioCentury | Jul 18, 2024
Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
BioCentury | May 21, 2024
Emerging Company Profile
Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale
Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers
BioCentury | Mar 21, 2024
Finance
Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail
Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
Items per page:
1 - 10 of 60